531 related articles for article (PubMed ID: 21240023)
1. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
Collins BS; Lin HC
J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
[TBL] [Abstract][Full Text] [Related]
4. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
Weinstock LB; Geng B; Brandes SB
Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
[TBL] [Abstract][Full Text] [Related]
5. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation.
Collins BS; Lin HC
Dig Dis Sci; 2010 Jan; 55(1):124-30. PubMed ID: 19888655
[TBL] [Abstract][Full Text] [Related]
6. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
7. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
8. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study.
Pimentel M; Chow EJ; Lin HC
Am J Gastroenterol; 2003 Feb; 98(2):412-9. PubMed ID: 12591062
[TBL] [Abstract][Full Text] [Related]
9. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study.
Scarpellini E; Giorgio V; Gabrielli M; Lauritano EC; Pantanella A; Fundarò C; Gasbarrini A
J Pediatr; 2009 Sep; 155(3):416-20. PubMed ID: 19535093
[TBL] [Abstract][Full Text] [Related]
11. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.
Sharara AI; Aoun E; Abdul-Baki H; Mounzer R; Sidani S; Elhajj I
Am J Gastroenterol; 2006 Feb; 101(2):326-33. PubMed ID: 16454838
[TBL] [Abstract][Full Text] [Related]
13. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
[TBL] [Abstract][Full Text] [Related]
14. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
[TBL] [Abstract][Full Text] [Related]
15. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome.
Rana SV; Sharma S; Kaur J; Sinha SK; Singh K
Digestion; 2012; 85(3):243-7. PubMed ID: 22472730
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.
Boltin D; Perets TT; Shporn E; Aizic S; Levy S; Niv Y; Dickman R
Ann Clin Microbiol Antimicrob; 2014 Oct; 13():49. PubMed ID: 25319626
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
[TBL] [Abstract][Full Text] [Related]
18. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Majewski M; McCallum RW
Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
[TBL] [Abstract][Full Text] [Related]
19. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Meyrat P; Safroneeva E; Schoepfer AM
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
